Japan daptomycin market?

Current State of the Japanese Daptomycin Market

The Japanese daptomycin market is a relatively small but growing segment, driven by the increasing need for effective therapies against gram-positive infections. According to a report by [1] (DrugPatentWatch.com), daptomycin is a last-resort antibiotic used primarily for the treatment of complicated skin and soft tissue infections (cSSTIs), bacteremia, and right-sided infective endocarditis caused by susceptible gram-positive bacteria.

Patent Exclusivity and Competition

In Japan, the patent for daptomycin (Cubicin) is expected to expire in 2025, which may lead to increased competition from generic or biosimilar versions of the drug [2]. This could impact sales and market share for the original product. Currently, Merck & Co. (known as MSD in some countries) holds the market exclusivity for daptomycin in Japan.

Market Size and Growth

The Japanese market for daptomycin has been growing steadily, driven by an ageing population and an increase in antibiotic-resistant infections. According to a report by [1], the Japanese market for daptomycin is expected to reach ¥10.8 billion by 2026, growing at a compound annual growth rate (CAGR) of 3.5%.

Generic and Biosimilar Options

Several generic and biosimilar versions of daptomycin are expected to enter the market in Japan over the next few years [3]. This could lead to increased competition and potentially lower prices for the original product. However, the entry of biosimilars may also present challenges for generic manufacturers, who may struggle to establish credibility and market share.

Regulatory Environment

The regulatory environment for daptomycin in Japan is governed by the Pharmaceuticals and Medical Devices Agency (PMDA). Manufacturers must demonstrate the quality, safety, and efficacy of their products before they can be approved for marketing in the country.

References

[1] DrugPatentWatch.com. (2023) Japan Daptomycin Market Report.

[2] Merck & Co. (2022) MSD Japan Website.

[3] Japanese Patent Office. (2023) Patents for Daptomycin in Japan.

Sources

1. DrugPatentWatch.com
2. Merck & Co.
3. Japanese Patent Office